WHO Advisers Recommend Restricting Ebola Treatments to Clinical Trial Use

Summary:
Advisers to the World Health Organization have recommended that experimental medicines being developed for the Ebola outbreak in the Democratic Republic of the Congo and Uganda should only be used within clinical trials to ensure safe and reliable research outcomes. The guidance means infected individuals or those exposed to the virus may not immediately receive these treatments outside trial settings. WHO expert panels reviewing therapies for the Bundibugyo strain stressed the need for controlled studies because Ebola outbreaks are unpredictable, occur in remote regions, and progress rapidly. However, the recommendation could face resistance, as the United States reportedly plans to provide monoclonal antibody treatments to infected Americans through a medical facility in Kenya. 

Medicines currently being developed to treat and prevent infections linked to the Ebola virus circulating in the Democratic Republic of the Congo and Uganda should only be administered within clinical trial settings, advisers to the World Health Organization have recommended.

As a result, individuals who are currently infected or those exposed to the virus and at risk of infection may not immediately receive access to these treatments. Developing effective Ebola therapies has remained highly challenging because outbreaks occur unpredictably, often in remote regions, and the disease progresses rapidly with high fatality rates.

The WHO brought together multiple expert advisory panels to evaluate potential therapies targeting the Bundibugyo strain presently spreading in affected regions. The experts advised that all candidate products should “be used exclusively within clinical trials to generate robust data and ensure safe, ethical, and effective research,” the organisation stated.

However, the recommendation may face opposition. According to a White House official, the United States plans to make monoclonal antibody treatments available to infected American citizens. The official said during a media briefing on Thursday that these treatments would be accessible at a medical facility in Kenya for Americans exposed to the virus.